Twenty-seven stable male patients over 50 years who were under maintenance continuous ambulatory peritoneal dialysis ( CAPD ) therapy were randomized to receive recombinant human erythropoietin ( rHuEPO ; N = 14 ) or nandrolone decanoate ( ND ; 200 mg/week IM ; N = 13 ) as therapy for anemia .
